Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06450041
Title NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New Approaches to Neuroblastoma Therapy Consortium
Indications
Therapies
Age Groups: child | adult
Covered Countries USA

Facility Status City State Zip Country Details
Children's Hospital Los Angeles RECRUITING Los Angeles California 90027-0700 United States Details
UCSF Benioff Children's Hospital NOT_YET_RECRUITING San Francisco California 94143 United States Details
Children's Hospital Colorado NOT_YET_RECRUITING Aurora Colorado 80045 United States Details
Comer Children's Hospital, University of Chicago NOT_YET_RECRUITING Chicago Illinois 60614 United States Details
Boston Children's Hospital, Dana-Farber Cancer Institute. NOT_YET_RECRUITING Boston Massachusetts 02115 United States Details
C.S Mott Children's Hospital NOT_YET_RECRUITING Ann Arbor Michigan 48109 United States Details
Cincinnati Children's Hospital Medical Center NOT_YET_RECRUITING Cincinnati Ohio 45229-3039 United States Details
Nationwide Children's Hospital NOT_YET_RECRUITING Columbus Ohio 43205 United States Details
Children's Hospital of Philadelphia NOT_YET_RECRUITING Philadelphia Pennsylvania 19104-4318 United States Details
St. Jude Children's Research Hospital NOT_YET_RECRUITING Memphis Tennessee 38105 United States Details
University of Texas Southwestern NOT_YET_RECRUITING Dallas Texas 75235 United States Details
Cook Children's Medical Center NOT_YET_RECRUITING Fort Worth Texas 76104 United States Details
Seattle Children's Hospital NOT_YET_RECRUITING Seattle Washington 98105 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field